Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
2.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
3.
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
4.
Commercial Insight: CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
5.
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market
6.
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
7.
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
8.
Stakeholder Opinions: Heart Failure - When drugs do not work
9.
Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates
10.
Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential
Best Sellers:
1.
Primary Brain Cancer
2.
Drug Delivery Global Industry Guide
3.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
4.
The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles
5.
BioNewsCast Press Release Distribution Service
6.
Pharmaceutical Growth Opportunities in Brazil, Russia, India and China - Healthcare reform, market dynamics and key players
7.
Cell Therapy - Technologies, Markets and Companies
8.
Cytogenetics - technologies, markets and companies
9.
Molecular Diagnostics Markets
10.
The Future of Targeted Therapeutics Key technologies, new therapy area applications and leading players
Prescribing Pharmacists - A Decision Maker Emerges
In five years, Kalorama Information believes the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will increase demand for drug decisions to be made at the pharmacist level.
This report, Prescribing Pharmacists, a Decision Maker Emerges details the reasons behind this change and defines the roles of the new decision makers that pharmaceutical companies will have to incorporate into strategy. In the U.S. healthcare market the role of the pharmacist is changing. This report details the tremendous transformation occuring.
As this report details, pharmacists already have a huge impact on drug revenues, and companies that do not develop a marketing strategy involving this important decision maker will lose advantage in the coming years. Pharmacists are moving from their role dispensing medications based on phsyician instructions, to prescribing based on physician diagnosis, to independent prescribing in some limited situations.
The States Most Likely to allow independent prescription in five years, and what states will follow.
The amount of drug revenues currently influenced by pharmacists, and forecasts to 2012.
The therapeutic areas most likely to see pharmacist influence.
Main drivers of the prescribing pharmacist trend.
Overview of state of Florida and Federal programs that already allow pharmacist prescription authority.
Useful background on the populations of pharmacists by area, their training pharmacists, and their role in drug purchases
Details on drug interactions and pharmacist role in reducing prescription errors
Extensive statistics on the U.S. health insurance trends that are driving prescribing trends
Review of cooperative therapy management programs already allowing pharmacists some prescriptive authority and how they operate in 43 states
Review of international pharmacy programs that allow prescriptive authority
This report is essential reading for anyone seeking to develop a marketing plan that addresses the increasing influence of pharmacists, and to be aware of and ready for their increasing direct control over prescriptions.
Kalorama's methodology involves a thorough search of government and company literature; but true insights come from interviews with company executives, members of state pharmacy boards, pharmacists and physicians. Over 200 of these individuals were interviewed for this report.
Marketing and business development directors in the pharmaceutical industry, as well as financial companies looking at broad trends in healthcare are among those who will benefit from this report.
September 1, 2007 117 Pages - Pub ID: KLI1492510 Format: PDF
Table of Contents
Sample Pages
Price: $1,995.00 / GBP997.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.